The Trump administration is blocking imports from BGI Group, BGI Genomics and MGI Tech beginning Thursday, with Customs and Border Protection responsible for barring the goods. DHS says the action is based on information linking the companies to Xinjiang and possible forced labor, while BGI denies any involvement. The restriction uses the Uyghur Forced Labor Prevention Act, signed in 2021, and follows an August expansion that brought the blacklist to 187 entities. The excerpt does not specify fees, importer forms, appeal procedures or the likely cost to businesses. The next concrete step is enforcement of the import bar by Customs and Border Protection.
TLDR: Customs and Border Protection is set to block goods from three BGI-affiliated biotech companies under a law addressing forced-labor risks. DHS cites reported links to Xinjiang, while BGI disputes the allegations; details on fees, importer paperwork and appeals are not provided.
The Trump administration is blocking imports from BGI Group and its affiliates, citing allegations of forced labor connected to China’s Xinjiang region. U.S. Customs and Border Protection is scheduled to begin barring goods from BGI Group, BGI Genomics and MGI Tech on Thursday. The action is being taken under the Uyghur Forced Labor Prevention Act, which has been in effect since 2021.
The administration’s stated rationale is that the companies may be sourcing materials from Xinjiang or working with the regional government in ways connected to forced labor. The Department of Homeland Security said it relied on “credible information, including corporate and government reporting.” It also said genetic testing supported by the companies could facilitate surveillance and repression of ethnic minorities, including Uyghurs. Those are government allegations, not findings established in the excerpt.
The affected businesses operate in biotechnology. BGI Group is known for genetic sequencing technologies, and DHS said it has controlling stakes in BGI Genomics and MGI Tech. The agency said the companies supported genetic testing in Xinjiang. Its announcement links that activity to concerns about the collection and analysis of genetic material and the potential use of such information by the Chinese government.
BGI Group rejected the forced-labor allegations. In a statement Wednesday, it said it “has not engaged in any form of forced labor” and added that it opposes forced labor. The Chinese government has also refuted claims about Xinjiang as lies and described its policies there as efforts to fight terror and ensure stability. The competing statements are part of the public record; the excerpt does not provide an independent determination resolving them.
The import restriction also sits within a wider U.S.-China economic and technology competition. Biotechnology has emerged as another area of tension. The Treasury Department proposed new restrictions last week on U.S. investments involving biotechnology, artificial intelligence and supercomputing in countries such as China. That proposal is separate from the import action and is not described as a final rule in the excerpt.
BGI has been a concern to U.S. lawmakers and policymakers for several years. The excerpt says their concerns include alleged ties to the Chinese government and the company’s access to large amounts of genetic data, which they fear could affect U.S. national security and commercial interests. BGI has emphasized its private ownership and said it does not serve patients in the United States or have access to Americans’ genetic data.
Congress did not pass legislation specifically barring BGI from doing business with federally funded medical providers. It did pass a similar provision at the end of last year without naming companies, asking for a list of biotechnology companies of concern to be compiled. The Pentagon has separately labeled BGI Group, BGI Genomics and MGI Tech Chinese military companies, a designation the excerpt says carries reputational damage. These measures form part of a broader policy record, but they are distinct from the new customs restriction.
The new restrictions operate under the Uyghur Forced Labor Prevention Act, signed into law at the end of 2021 after allegations of human rights abuses against Uyghurs and other Muslim minorities in Xinjiang. In August, the Trump administration added 43 Chinese companies to the law’s blacklist, bringing the stated total to 187 entities. The administration says the policy is intended to prevent goods connected to forced labor from entering the United States and to protect American workers from being undercut by foreign companies using such labor.
The immediate practical impact is a prohibition on goods from the three named companies beginning Thursday. Customs and Border Protection is the enforcement agency identified in the announcement. The excerpt gives no fee, importer paperwork, appeal process, shipment-by-shipment procedure or separate compliance deadline, so those details are not specified here. Importers and other businesses handling goods from the named companies are directly affected by the bar, though the excerpt does not describe the scale of shipments or the expected costs.
The restriction is part of an existing law and an expanded blacklist, rather than a new investment rule. The administration’s next stated step is implementation by Customs and Border Protection on Thursday. That enforcement date and the agency’s role are necessary steps in applying the restriction; the excerpt does not identify additional oversight arrangements or provide an assurance about how disputed allegations will be reviewed.

